| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
59,065,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tyra Biosciences is an oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Co. is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR family. Co.'s lead product candidate, TYRA-300, is designed to selectively inhibit Fibroblast Growth Factor Receptor3, with an initial focus on patients with bladder cancer. In addition, Co. has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase, and FGFR4-related cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
163,287 |
1,561,335 |
2,791,516 |
| Total Buy Value |
$0 |
$1,664,700 |
$15,320,005 |
$35,308,025 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
3 |
6 |
8 |
| Total Shares Sold |
503,871 |
565,263 |
600,530 |
1,206,057 |
| Total Sell Value |
$9,139,017 |
$9,767,281 |
$10,329,717 |
$21,934,630 |
| Total People Sold |
2 |
3 |
4 |
5 |
| Total Sell Transactions |
6 |
11 |
16 |
53 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  More Robert J |
|
– • – |
2025-11-21 |
4 |
AS |
$20.25 |
$5,000,026 |
I/I |
(246,871) |
3,833,425 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2025-11-19 |
4 |
AS |
$16.32 |
$815,297 |
D/D |
(49,956) |
170,981 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2025-11-18 |
4 |
AS |
$16.07 |
$1,215,627 |
D/D |
(75,633) |
220,937 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2025-11-17 |
4 |
AS |
$16.11 |
$324,798 |
D/D |
(20,072) |
296,570 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2025-11-14 |
4 |
AS |
$16.02 |
$1,765,489 |
D/D |
(110,228) |
316,642 |
|
- |
|
| Bensen Daniel |
Chief Operating Officer |
• – – |
2025-11-13 |
4 |
AS |
$16.00 |
$17,780 |
D/D |
(1,111) |
426,870 |
|
- |
|
| Fuhrman Alan |
Chief Financial Officer |
• – – |
2025-09-15 |
4 |
A |
$9.13 |
$6,399 |
D/D |
701 |
14,788 |
|
- |
|
| Kaplan Gilla Phd |
|
– • – |
2025-06-18 |
4 |
S |
$9.78 |
$93,596 |
D/D |
(9,568) |
28,231 |
|
- |
|
| Kaplan Gilla Phd |
|
– • – |
2025-06-17 |
4 |
S |
$10.35 |
$104 |
D/D |
(10) |
37,799 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-16 |
4 |
B |
$10.13 |
$119,666 |
I/I |
11,813 |
10,259,291 |
2.25 |
- |
|
| Kaplan Gilla Phd |
|
– • – |
2025-06-16 |
4 |
S |
$10.38 |
$70,726 |
D/D |
(6,814) |
37,809 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-13 |
4 |
B |
$10.20 |
$1,225,703 |
I/I |
120,167 |
10,247,478 |
2.25 |
- |
|
| Kaplan Gilla Phd |
|
– • – |
2025-06-13 |
4 |
S |
$10.31 |
$154,583 |
D/D |
(15,000) |
44,623 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-12 |
4 |
B |
$10.20 |
$319,331 |
I/I |
31,307 |
10,127,311 |
2.25 |
- |
|
| Kaplan Gilla Phd |
|
– • – |
2025-06-12 |
4 |
S |
$10.31 |
$309,255 |
D/D |
(30,000) |
59,623 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-09 |
4 |
B |
$10.19 |
$1,904,002 |
I/I |
186,850 |
10,096,004 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-05 |
4 |
B |
$10.04 |
$2,141,873 |
I/I |
213,334 |
9,909,154 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-06-04 |
4 |
B |
$9.63 |
$9,609,430 |
I/I |
997,864 |
9,695,820 |
2.25 |
- |
|
| Harris Todd |
President and CEO |
• • – |
2025-03-14 |
4 |
A |
$9.78 |
$12,131 |
D/D |
1,241 |
1,357,168 |
|
- |
|
| Fuhrman Alan |
Chief Financial Officer |
• – – |
2025-03-14 |
4 |
A |
$9.78 |
$12,101 |
D/D |
1,238 |
14,087 |
|
- |
|
| Kjellson Nina S |
|
– • – |
2025-02-05 |
4 |
S |
$13.76 |
$74,324 |
I/I |
(5,401) |
443,885 |
|
- |
|
| Gulfo Adele M. |
|
– • – |
2025-01-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000 |
|
- |
|
| Kjellson Nina S |
|
– • – |
2025-01-23 |
4 |
S |
$16.26 |
$78,466 |
I/I |
(4,825) |
3,702,595 |
|
- |
|
| Kjellson Nina S |
|
– • – |
2025-01-21 |
4 |
S |
$16.36 |
$65,336 |
I/I |
(3,993) |
3,707,420 |
|
- |
|
| Kjellson Nina S |
|
– • – |
2025-01-17 |
4 |
S |
$16.40 |
$217,613 |
I/I |
(13,269) |
447,396 |
|
- |
|
191 Records found
|
|
Page 1 of 8 |
|
|
